Skip to main content
Publications
Tormos A , Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D , Garcia Esteban R , Plana E , Farsani SF, Perez-Gutthann S , Pladevall-Vila M , Rebordosa C . Post-authorisation safety study (PASS) assessing the risk of liver, renal, genitourinary, and diabetic ketoacidosis outcomes among users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes mellitus (T2D) . Poster presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):585. doi: 10.1002/pds.5687
Anthony MS , Djebarri L, Beachler DC, Aroda VR, Calingaert B , Pan C, Crowe C, Lanes S, Rothman KJ , Saltus CW , Berreghis S, Parlett LE, Bocage C, Walsh KE, Juhaeri J, Johannes C . Risk of anaphylaxis among new users of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) . Poster presented at the American Diabetes Association's 83rd Scientific Sessions; June 23, 2023. San Diego, CA. [abstract] Diabetes. 2023 Jun 20; 72(supplement_1):846-P. doi: 10.2337/db23-846-P
Zhou CK, Dinh J, Danysh HE , Johannes C , Gutierrez L , Schmid R, Arana A , Kaye JA, Pladevall-Vila M , Garcia-Albeniz X , Gangemi K, Yin R, Ruzafa JC, Gilsenan A , Beachler DC. Validity of claims-based algorithms to identify acute kidney injury, acute liver injury, severe complications of urinary tract infections, breast cancer, and bladder cancer among patients with type 2 diabetes: a pilot study . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):317. doi: 10.1002/pds.4864
Gutierrez L , Beachler DC, Overbeek J, McQuay L, Yin R, Kuiper J, McGrath L, Jemison J, Houben E, Lanes S, Gilsenan A , Herrings R. Characteristics of new users of dapagliflozin and other antidiabetic drugs: United States, United Kingdom, and the Netherlands . Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):128.
Gil M, Romio S, Scotti L, Leal I, Masclee GMC, Schmedt N, Varas-Lorenzo C, Pladevall-Vila M , Smits MM, Bezemer I, Seeger JD, de Beradis G, Pecchioli S, Trifiro G, McGrogan A, Rijnbeek P, Sturkenboom M. Risk of hemorrhagic stroke associated with non-insulin blood glucose lowering drugs. Results from the SAFEGUARD project . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):428-9.
Masclee GMC, Leal I, Scotti L, De Berardis G, Bezemer I, Gil M, McGrogan A, Schmedt N, Seeger JD, Trifiro G, Pecchioli S, Pladevall-Vila M , Smits MM, Rijnbeek P, Sturkenboom M, Romio SA. Use of non-insulin blood glucose lowering drugs and the risk of acute pancreatitis . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):246-7.
Doward L , Højbjerre L, Hogue S, Fernandez M, Barrett A , Crawford R , Kragh N, Aagren M. Influence of patient-reported outcomes on regulatory, HTA, and market access decisions: obesity and diabetes case examples . Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015; 18:A1-A333.